[A23-131] Nivolumab (NSCLC, neoadjuvant) – Addendum to Project A23-74
Last updated 01.02.2024
Project no.:
A23-131
Commission:
Commission awarded on 12.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A23-131
| Project no. | Title | Status |
|---|---|---|
| A23-74 | Nivolumab (NSCLC, combination with platinum-based chemotherapy, neoadjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-02-01 A G-BA decision was published.